EUCTR2020-001348-25-PT
Active, not recruiting
Phase 1
A multicentre study to assess safety and efficacy of psilocybin in patients with treatment-resistant depression following completion of COMP 001 and COMP 003 trials (P-TRD LTFU)
COMPASS Pathways, Ltd0 sites150 target enrollmentMay 7, 2020
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- COMPASS Pathways, Ltd
- Enrollment
- 150
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\)Signed ICF
- •2\)Each participant having completed the final study visit of either COMP 001 or COMP 003
- •3\)Ability to complete all protocol required assessment tools (including having access to the internet in order to complete the digital assessments) without any assistance or alteration to the copyrighted assessments, and to comply with all study visits
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 126
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 24
Exclusion Criteria
- •1\)Subject has any condition, for which in the opinion of the investigator, participation would not be in the interest of the subject eg participation could compromise the wellbeing of the participant or prevent, limit, or confound the protocol\-specified assessments
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A multicentre study to assess safety and efficacy of COMP360 in patients with treatment-resistant depression following completion of COMP 001 and COMP 003 trials (P-TRD LTFU)treatment resistant depression10027946NL-OMON55052COMPASS Pathfinder Ltd3
Active, not recruiting
Phase 1
ong Term Follow up study for subjects that participated in COMP001 and COMP003 trialTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2020-001348-25-CZCOMPASS Pathfinder, Ltd150
Active, not recruiting
Phase 1
ong Term Follow up study for subjects that participated in COMP001 and COMP003 trialTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2020-001348-25-NLCOMPASS Pathfinder, Ltd150
Active, not recruiting
Phase 1
ong Term Follow up study for subjects that participated in COMP001 and COMP003 trialTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2020-001348-25-DECOMPASS Pathfinder, Ltd150
Active, not recruiting
Phase 1
ong Term Follow up study for subjects that participated in COMP001 and COMP003 trialTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2020-001348-25-DKCOMPASS Pathfinder, Ltd150